How Replior’s integrated UV monitoring improves patient engagement in the Almirall AKtive trial, a phase IV study.

The SCAPIS study collected and analyzed 30+ million data points from 30,154 participants with Replior.

Learn how Almirall reached 93% patient retention and 94% diary compliance in a Phase III actinic keratosis trial using Trial Online ePRO and gamification features.